Stock Analiz

DBV Technologies S.A. DBVT

Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2014 · data as of November 13, 2026

$11.02Market cap $693M
Open the interactive analysis →

DBV Technologies S.A. (DBVT) is a healthcare company listed in the US with a market value of about $693M. In fiscal year 2025 it had revenue of $6M and net income of -$147M, a net margin of -2607.3%.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of -13% a year, a 5-year average ROIC of -101%.

About DBV Technologies

DBV Technologies is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2014. Revenue went from $7M in 2015 to $6M in 2025, a decline of about 1.7% a year. It was profitable in 2 of the last 10 years in our data. It spends 2070% of revenue on research and development.

Score: 1.0 / 5

Value0/5
Future growth3/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S185.4
P/B4.7
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-17.6%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)35.8%
Revenue growth (5 yrs, per year)-13.0%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-2355.1%
ROIC (5-yr avg.)-100.8%
Profitable years (of last 10)2
Years paying a dividend—

Financials, last 10 years

Fiscal year2025202420232022202120202019201820172016
Revenue$6M$4M——$6M$11M$15M$17M$14M$10M
Net income-$147M-$114M$73M$96M-$98M-$160M-$172M-$190M-$177M-$121M
Free cash flow-$122M-$107M-$80M-$56M-$109M-$168M-$154M-$162M-$146M-$71M
EPS (diluted)$-2.34$-1.81$1.16$1.53$-1.56$-2.54$-2.74$-3.02$-2.82$-1.92
Net margin-2607.3%-2744.3%——-1713.5%-1415.0%-1169.5%-1142.4%-1240.2%-1260.8%
ROIC-66.3%-268.2%-41.4%-38.7%-89.3%-71.9%-61.3%-106.1%-85.4%-46.9%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 6 analysts is $41.93, 281% above the current price; targets range from $29.66 to $47.38; the consensus rating is “Buy”; expected EPS is $-0.41 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does DBV Technologies pay a dividend?

Not currently.

Is DBV Technologies a good stock to buy?

We do not give buy or sell advice. DBV Technologies scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.